CDER approved 46 novel drugs in 2025, half for rare diseases
Regulatory NewsJoanne S. Eglovitch
Advanced therapies/cell and gene therapyApproval/marketing authorizationCDERExpedited pathwaysPharmaceuticalsProduct developmentRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)